ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY)

Historical Holders from Q1 2014 to Q4 2025

Symbol: ALNY on Nasdaq
Type / Class: Equity / COMMON STOCK
Shares outstanding: 131,516,365
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 129,488,588
Holdings value: $59,035,794,339
% of all portfolios: 0.03%
Number of holders: 810
Number of buys: 492
Number of sells: 270
Average buys %: +0.01%
Average sells %: -0.03%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) based on Schedule 13D/G filings

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
FMR LLC	13%	$7,676,347,201	16,834,095	FMR LLC	30 Sep 2025
VANGUARD GROUP INC	10%	$3,041,536,135	13,056,605	The Vanguard Group	31 Mar 2025
Capital Research Global Investors	5.4%	$1,623,315,103	6,968,513	Capital Research Global Investors	31 Dec 2024

As of 30 Sep 2025 ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 810 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 129,488,588 shares of 131,516,365 outstanding shares and own 98% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) own 76% of the company based on 13F filings as of 30 Sep 2025

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
FMR LLC	13%	16,767,625	+6.1%	0.4%	$7,646,036,992
Capital World Investors	12%	16,434,253	-2.2%	1%	$7,493,808,123
VANGUARD GROUP INC	10%	13,565,452	+2%	0.09%	$6,185,846,112
BlackRock, Inc.	7.5%	9,903,601	-0.77%	0.08%	$4,516,042,243
Capital Research Global Investors	5.5%	7,222,840	+0.43%	0.62%	$3,293,515,969
JPMORGAN CHASE & CO	3.5%	4,543,770	+120%	0.13%	$2,071,971,357
STATE STREET CORP	2.3%	3,081,475	-2.9%	0.05%	$1,405,152,600
BAILLIE GIFFORD & CO	2.1%	2,789,356	-8%	0.94%	$1,271,946,336
GEODE CAPITAL MANAGEMENT, LLC	1.9%	2,499,242	+4.2%	0.07%	$1,136,405,944
Dodge & Cox	1.8%	2,321,230	-27%	0.57%	$1,058,480,880
T. Rowe Price Investment Management, Inc.	1.7%	2,173,984	-49%	0.61%	$991,337,000
Orbis Allan Gray Ltd	1.5%	1,950,962	-8%	3.8%	$889,638,672
WELLINGTON MANAGEMENT GROUP LLP	1.4%	1,826,321	-12%	0.15%	$832,802,376
PRICE T ROWE ASSOCIATES INC /MD/	1.4%	1,800,294	-43%	0.09%	$820,935,000
AMERICAN CENTURY COMPANIES INC	1.2%	1,641,441	-8.5%	0.38%	$748,499,727
BANK OF AMERICA CORP /DE/	1.1%	1,498,491	+19%	0.05%	$683,311,896
Invesco Ltd.	1.1%	1,481,842	+10%	0.11%	$675,719,852
REGENERON PHARMACEUTICALS, INC.	1.1%	1,392,303	-69%	91%	$634,890,168
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	1%	1,355,609	+699%	0.39%	$618,157,704
JANE STREET GROUP, LLC	0.73%	958,750	+4095%	0.51%	$437,190,000
TWO SIGMA ADVISERS, LP	0.68%	892,500	+235%	0.81%	$406,980,000
Legal & General Group Plc	0.68%	887,780	+1.7%	0.09%	$404,827,688
NORTHERN TRUST CORP	0.63%	833,151	+0.17%	0.05%	$379,916,856
Qube Research & Technologies Ltd	0.62%	811,278		0.52%	$369,942,768
AQR CAPITAL MANAGEMENT LLC	0.57%	744,008	+295%	0.22%	$336,009,047

Institutional Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	13,517	$5,375,334	-$1,556,052			$397.65	10
2025 Q3	129,488,588	$59,035,794,339	-$785,853,708	$621,709,338	$534,769,985	$456.00	810
2025 Q2	132,062,946	$43,060,444,035	+$1,728,282,698	$178,418,527	$162,891,100	$326.09	645
2025 Q1	126,818,148	$34,215,987,703	-$90,166,830	$204,331,684	$241,096,201	$270.02	613
2024 Q4	127,611,269	$30,032,119,087	+$340,572,364	$152,133,947	$176,466,906	$235.31	580
2024 Q3	121,365,852	$33,378,590,552	+$487,748,875	$308,250,279	$336,249,601	$275.03	559
2024 Q2	119,941,359	$29,151,034,661	+$1,980,827,647	$500,482,800	$546,799,100	$243.00	517
2024 Q1	112,371,900	$16,793,789,553	-$858,924,993	$247,936,415	$405,517,470	$149.45	492
2023 Q4	427,849	$82,017,555	-$16,166,867			$191.41	8
2023 Q3	115,468,014	$20,442,238,689	-$245,878,270	$159,386,540	$148,909,589	$177.10	436
2023 Q2	116,681,820	$22,168,493,440	-$421,542,751	$130,155,176	$101,759,146	$189.94	457
2023 Q1	118,704,363	$23,765,293,877	+$26,402,245	$114,389,520	$168,915,720	$200.32	459
2022 Q4	118,398,438	$28,126,591,911	-$3,103,877,529	$173,822,485	$326,037,555	$237.65	467
2022 Q3	132,620,120	$26,554,392,644	+$3,402,968,415	$142,423,976	$253,230,768	$200.16	463
2022 Q2	112,960,810	$16,459,439,315	-$76,904,527	$260,321,785	$422,172,830	$145.85	397
2022 Q1	113,392,085	$18,514,227,539	+$219,294,031	$170,925,484	$121,205,000	$163.29	411
2021 Q4	111,482,203	$18,900,371,043	+$64,975,324	$158,541,236	$204,897,000	$169.58	411
2021 Q3	111,097,170	$20,972,807,544	-$165,142,050	$114,792,202	$262,864,000	$188.81	390
2021 Q2	111,812,148	$18,955,218,376	+$508,317,710	$228,027,400	$265,030,000	$169.52	389
2021 Q1	108,723,456	$15,341,750,136	+$197,050,273	$50,917,000	$82,457,950	$141.19	377
2020 Q4	106,756,225	$13,870,060,866	-$100,610,236	$117,040,091	$97,589,568	$129.97	342
2020 Q3	108,385,876	$15,772,967,440	-$457,393,605	$124,305,000	$124,325,000	$145.60	341
2020 Q2	111,428,906	$16,502,827,030	+$493,239,882	$111,645,000	$125,489,000	$148.11	358
2020 Q1	108,175,646	$11,775,283,696	+$281,943,769	$118,203,000	$134,857,000	$108.85	311
2019 Q4	105,115,918	$12,104,676,649	-$227,115,733	$110,696,000	$128,573,000	$115.17	301
2019 Q3	106,791,396	$8,587,885,990	+$172,158,251	$65,643,000	$99,390,000	$80.42	269
2019 Q2	105,900,426	$7,682,385,508	+$882,314,454	$52,489,000	$55,704,000	$72.56	278
2019 Q1	94,729,843	$8,851,809,866	+$410,227,412	$43,764,000	$76,367,000	$93.45	272
2018 Q4	91,839,202	$6,693,183,477	+$108,404,837	$48,047,000	$113,479,000	$72.91	269
2018 Q3	90,501,081	$7,920,673,549	-$106,142,462	$92,320,000	$119,800,002	$87.52	293
2018 Q2	91,506,270	$9,012,076,725	+$41,261,249	$49,771,000	$93,570,000	$98.49	300
2018 Q1	91,148,433	$10,855,978,310	-$71,676,389	$89,621,000	$102,712,000	$119.10	282
2017 Q4	91,709,436	$11,651,473,167	+$606,378,261	$116,224,000	$148,107,000	$127.05	273
2017 Q3	87,434,843	$10,272,806,281	+$78,572,564	$263,201,000	$312,055,000	$117.49	225
2017 Q2	86,971,309	$6,930,234,907	+$483,097,113	$54,453,000	$72,141,000	$79.76	214
2017 Q1	82,264,429	$4,216,383,818	+$357,821,049	$26,897,005	$33,473,000	$51.25	187
2016 Q4	79,517,113	$2,977,362,834	-$14,483,242	$26,833,000	$27,792,000	$37.44	198
2016 Q3	77,421,858	$5,246,385,562	+$229,962,625	$26,093,000	$46,867,000	$67.78	248
2016 Q2	74,007,810	$4,106,674,677	+$154,567,977	$22,363,000	$57,797,000	$55.49	238
2016 Q1	70,198,619	$4,405,510,161	+$302,951,721	$46,016,000	$50,011,000	$62.77	243
2015 Q4	65,930,632	$6,206,779,299	+$91,300,709	$22,132,000	$18,006,000	$94.14	255
2015 Q3	63,440,286	$5,097,858,541	-$70,715,291	$30,235,000	$31,812,000	$80.36	251
2015 Q2	62,957,186	$7,546,668,459	+$115,920,788	$43,513,000	$35,960,000	$119.87	271
2015 Q1	64,445,072	$6,728,411,619	+$670,803,131	$56,081,000	$42,890,000	$104.42	233
2014 Q4	57,973,983	$5,623,402,197	-$127,237,878	$16,306,000	$31,000,000	$97.00	213
2014 Q3	58,977,372	$4,606,139,951	+$102,404,934	$46,641,000	$44,959,000	$78.10	184
2014 Q2	57,779,618	$3,648,879,764	+$129,623,911	$32,675,000	$34,755,000	$63.17	193
2014 Q1	55,704,223	$3,739,161,613	+$17,923,358	$55,183,000	$25,361,000	$67.14	193